Multi-omics reveals deoxycholic acid modulates bile acid metabolism via the gut microbiota to antagonize carbon tetrachloride-induced chronic liver injury

Article

作者: Chen, Tianbin ; Zeng, Yongjun ; Lin, Caorui ; Zhang, Li ; Ou, Qishui ; Huang, Huanhuan ; Yi, Qiang ; Zeng, Yongbin ; Zheng, Zhiyi ; Fu, Ya ; Liu, Can

Deoxycholic acid (DCA) serves essential functions in both physiological and pathological liver processes; nevertheless, the relationship among DCA, gut microbiota, and metabolism in chronic liver injury remain insufficiently understood. The primary objective of this study is to elucidate the potential of DCA in ameliorating chronic liver injury and evaluate its regulatory effect on gut microbiota and metabolism via a comprehensive multi-omics approach. Our study found that DCA supplementation caused significant changes in the composition of gut microbiota, which were essential for its antagonistic effect against CCl₄-induced chronic liver injury. When gut microbiota was depleted with antibiotics, the observed protective efficacy of DCA against chronic liver injury became noticeably attenuated. Mechanistically, we discovered that DCA regulates the metabolism of bile acids (BAs), including 3-epi DCA, Apo-CA, and its isomers 12-KLCA and 7-KLCA, IHDCA, and DCA, by promoting the growth of A.muciniphila in gut microbiota. This might lead to the inhibition of the IL-17 and TNF inflammatory signaling pathway, thereby effectively countering CCl₄-induced chronic liver injury. This study illustrates that the enrichment of A. muciniphila in the gut microbiota, mediated by DCA, enhances the production of secondary bile acids, thereby mitigating chronic liver injury induced by CCl₄. The underlying mechanism may involve the inhibition of hepatic IL-17 and TNF signaling pathways. These findings propose a promising approach to alleviate chronic liver injury by modulating both the gut microbiota and bile acids metabolism.

2024-12-01·JOURNAL OF ETHNOPHARMACOLOGY

Integrating serum pharmacochemistry, network pharmacology and untargeted metabolomics strategies to reveal the material basis and mechanism of action of Feining keli in the treatment of chronic bronchitis

Article

作者: Zhu, Zhu ; Wu, Jia-Jun ; Yang, Yong-Run ; Zou, Yun-Lu ; Feng, Ya-Dong ; Wang, Lin ; Xu, Wei ; Jiang, Xiao-Xue ; Xiao, Ying-Hao

ETHNOPHARMACOLOGICAL RELEVANCE:

Feining keli (FNKL) is herbal preparation mainly made from Senecio cannabifolius Less., In recent years, more and more studies have found that FNKL has excellent therapeutic effects on chronic bronchitis (CB). Nevertheless, its pharmacodynamic material basis and mechanism of action are still unknown.

AIM OF THE STUDY:

This study aimed to explore the pharmacodynamic material basis and mechanism of action of FNKL in treating CB.

MATERIALS AND METHODS:

The CB rat model was induced using nasal drops of lipopolysaccharide (LPS) in combination with smoking. Various assessments including behavioral and body mass examination, lung index measurement, enzyme linked immunosorbent assay (ELISA), as well as histological analyses using hematoxylin and eosin (H&E) and Masson staining were conducted to validate the reliability of the CB model. The serum components of FNKL in CB rats were identified using ultra-high-performance liquid chromatography Orbitrap Exploris mass spectrometer (UHPLC-OE-MS). Network pharmacology was used to predict the network of action of the active ingredients in FNKL based on these serum components. Signaling pathways were enriched and analyzed, and molecular docking was conducted for key targets. Molecular dynamics simulations were performed using GROMACS software. The mechanism was confirmed through a series of experiments including Western blot (WB), immunofluorescence (IF), and reverse transcription (RT)-PCR. Additionally, untargeted metabolomics was employed to identify biomarkers and relevant metabolic pathways associated with the treatment of CB with FNKL.

RESULTS:

In CB rats, FNKL improved body mass, lung index, and pathological damage of lung tissues. It also decreased interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), malonaldehyde (MDA) levels, and percentage of lung collagen fiber area. Furthermore, FNKL increased IL-10 and superoxide dismutase (SOD) levels, which helped alleviate bronchial inflammation in the lungs. A total of 70 FNKL chemical components were identified in CB rat serum. Through network pharmacology analysis, 5 targets, such as PI3K, AKT, NF-κB, HIF-1α, and MYD88, were identified as key targets of FNKL in the treatment of CB. Additionally, the key signaling pathways identified were PI3K/AKT pathway、NF-κB/MyD88 pathway、HIF-1α pathway. WB, IF, and RT-PCR experiments were conducted to confirm the findings. Molecular docking studies demonstrated successful docking of 16 potential active components with 5 key targets. Additionally, molecular dynamics simulations indicated the stability of quercetin-3-galactoside and HIF-1α. Metabolomics analysis revealed that FNKL primarily regulated pathways related to alpha-linolenic acid metabolism, primary bile acid biosynthesis, bile secretion, arachidonic acid metabolism, neuroactive ligand-receptor interaction, and folate biosynthesis. Furthermore, the expression levels of traumatic acid, traumatin, alpha linolenic acid, cholic acid, 2-arachidonoylglycerol, deoxycholic acid, 7,8-dihydroneopterin, and other metabolites were found to be regulated.

CONCLUSION:

FNKL exhibits positive therapeutic effects on CB, with quercetin-3-galactoside identified as a key active component. The mechanism of FNKL's therapeutic action on CB involves reducing inflammatory response, oxidative stress, and regulating metabolism, and its molecular mechanism was better elucidated in a holistic manner. This study serves as a reference for understanding the pharmacodynamic material basis and mechanism of action of FNKL in treating CB, and provides avenues for exploring the effects of compounded herbal medicines on CB.

2024-12-01·FOOD CHEMISTRY

The unfolded features on the synchronized fashion of gut microbiota and Drynaria rhizome against obesity via integrated pharmacology

Article

作者: Kim, Dong Joon ; Kim, Jeong Su ; Oh, Ki-Kwang ; Yoon, Sang-Jun ; Suk, Ki-Tae ; Park, Jeong Ha ; Kim, Min Ju ; Song, Seol Hee

Drynaria rhizome (DR) is used as a natural remedy to ameliorate obesity (OB) in East Asia; in parallel, the gut microbiota (GM) might exert a positive impact on OB through their metabolites. This study elucidates the orchestrated effects of DR and GM on OB. DR-GM, - a key signaling pathway-target-metabolite (DGSTM) networks were used to unveil the relationship between DR and GM, and Molecular Docking Test (MDT) and Density Functional Theory (DFT) were adopted to underpin the uppermost molecules. The NR1H3 (target) - 3-Epicycloeucalenol (ligand), and PPARG (target) - Clionasterol (ligand) conjugates from DR, FABP3 (target) - Ursodeoxycholic acid, FABP4 (target) - Lithocholic acid (ligand) or Deoxycholic acid (ligand), PPARA (target) - Equol (ligand), and PPARD (target) - 2,3-Bis(3,4-dihydroxybenzyl)butyrolactone (ligand) conjugates from GM formed the most stable conformers via MDT and DFT. Overall, these findings suggest that DR-GM might be a promising ameliorator on PPAR signaling pathway against OB.

项与脱氧胆酸相关的新闻（医药）

2024-08-01

·同写意

里程碑款3300万美元！圣诺医药RNAi疗法入局医美

临床申请siRNA临床2期核酸药物高管变更

2024-08-01

·美通社

圣诺医药宣布与Gore Range Capital合作成立Sagesse Bio，将RNAi疗法推向美容医学领域

香港、马里兰州德国城和苏州2024年8月1日 /美通社/ -- Sirnaomics Ltd. （「本公司」，股份代号：2257，连同其附属公司，统称「本集团」或「 Sirnaomics 圣诺医药」），一家行业领先的专注于探索及开发RNAi疗法的生物制药公司，今日宣布与Gore Range Capital（美国得克萨斯州达拉斯）合作，成立合资企业Sagesse Bio，Inc.，将其新型RNAi治疗产品推向美容医学领域。 Sagesse Bio，一家注册于美国特拉华州的公司，通过优化组合圣诺医药基于RNAi科技和产品开发方面的领导地位以及Gore Range Capital在皮肤健康行业世界领先的专业知识和财务资源，得以加快本公司创新药产品的临床开发，来应对和布局快速增长的美容医学市场。 Sagesse Bio将迅速开发圣诺医药已经在临床阶段（通过IND）的先导化合物。该药物已经处于并完成其他适应症的II期临床试验。最初关注的适应症包括塑身和减少脂肪。 Sagesse Bio公司创始人、董事会和新成立的执行管理团队由一群来自皮肤健康行业的优秀高管、世界知名的皮肤病学和美容医学临床医生以及RNAi医学领域的领先专家组成。 Sagesse Bio的战略目标是成为一家拥有创新技术和美容产品的世界领先的美容医学公司。 Frederick Beddingfield，医学博士，担任Sagesse Bio的董事会主席，是国际知名的皮肤科医生和生物制药和美容行业的专家，曾领导BOTOX®、JUVEDERM®、 LATISSE®和KYBELLA® 等全球领先品牌的开发。他曾担任Allergan Medical和Kythera的首席医疗官，以及Sienna Bio和Kira Pharmaceuticals的首席执行官，现时在Cytrellis Biosystems的董事会任职。 Beddingfield博士表示："我非常高兴能够帮助领导和建立Sagesse Bio。我们拥有一支经验丰富的团队，在人体临床研究中发现脂肪细胞溶解具有良好耐受性的基础上，拥有一个独特的机会，可以迅速推进我们已经获得IND准予的主导产品的临床试验。" Humberto Antunes先生，Sagesse Bio联合创始人、Gore Range Capital合伙人、Galderma/雀巢皮肤健康前董事长兼首席执行官、国际知名的皮肤健康行业高级经理人，评论道："Sagesse Bio的战略目标是为患者提供创新和改变生活的疗法，最初将侧重于局部脂肪重塑。" "我们很高兴能够建立这一历史性的合作伙伴关系：RNAi治疗候选药物正在进入医学美容产品开发领域，用于身体塑形，" 圣诺医药创始人兼执行董事、董事长、总裁兼首席执行官 Patrick Lu 博士评论道。 "圣诺医药和Gore Range Capital整合一体的专业知识和资源为Sagesse Bio的巨大增长潜力奠定了坚实的基础，从而能够加快其产品开发速度。" 圣诺医药董事会和公司管理团队，Sagesse Bio董事会和股东已经批准了一系列相关的合作协议。两家公司的管理团队已经签署了相关协议，并将在圣诺医药近期举行的股东大会上授权批准通过。根据合作协议，Sagesse Bio将在圣诺医药的科学和技术支持下，立即启动其主要候选产品SGY-101的临床研究，并获得与产品相关的知识产权的转让和授权。作为回报，圣诺医药将获得高达3300万美元的里程碑付款，以及在Sagesse Bio最低为6000万的融资前估值的股份或者债券的融资后，估值将达到3600万美元的Sagesse Bio的占据多数股份的权益。Gore Range Capital负责初始资金筹措，并已经组建了高级管理团队和顾问委员会。此外，凭借其在皮肤健康行业建立的领域专业知识和广泛的联系，Gore Range Capital能够为Sagesse Bio的融资和业务发展提供实践方法。关于 Gore Range Capital (GRC) Gore Range Capital（GRC）专注于皮肤健康业务的投资。 GRC的方法很简单：专门投资于所熟悉的领域和赛道。在团队成员各自的职业生涯中，GRC团队在医疗保健的多个领域建立了专业知识和广泛的网络。通过GRC可以专注于人类最大的且最能表现外貌和身份的器官——皮肤。 GRC可以通过运营为重点的私募股权投资的实践方法与风险投资所需的早期指导相结合。 GRC成立于2015年，旨在与行业先驱结成伙伴，与投资组合公司密切合作，将皮肤健康创新推向市场。为了完成这一使命，GRC利用已有的经验丰富的医疗保健投资者、领导者和从业者团队，为投资者和创业者提供战略、财务和科学专业知识的咨询。如需了解更多信息，请访问：www.gorerangecapital.com。关于 Sirnaomics Sirnaomics是一家RNA疗法生物制药公司，公司候选产品处于临床及临床前阶段，专注于探索及开发创新药物，用于治疗具有医疗需求及庞大市场机会的适应症。Sirnaomics是首家于亚洲和美国均拥有重要市场地位的临床阶段RNA疗法生物制药公司。凭借其专有的递送技术：多肽纳米颗粒递送平台和GalNAc偶联物递送平台，GalAhead™，本集团已建立非常丰富的候选药物管线。STP122G 是利用集团 GalAhead™ mxRNA 技术的首个候选药物，目前正处于第一阶段开发阶段。STP125G 是第二款基于 Sirnaomics 专利 GalAhead™ mxRNA 技术的 siRNA 治疗药物，以载脂蛋白 C3 mRNA 为靶点，用于心血管疾病的治疗。STP237G 是首个基于 GalAhead™ muRNA 技术的双靶向药物，目前处于临床前评估的后期阶段。通过 STP705 和 STP707 的临床项目，集团在肿瘤应用方面也取得了多项成功。随着Sirnaomics临床生产设施的建立，本集团专注实现从生物科技公司向生物制药公司的跃进。如欲了解更多关于公司信息，可浏览：www.sirnaomics.com。

临床申请siRNA高管变更核酸药物临床2期

2024-08-01

·PRNewswire

Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 31, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the " Company", Stock Code: 2257.HK, together with its subsidiaries, the " Group" or " Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced a partnership with Gore Range Capital LLC (" Gore Range Capital") (Dallas, TX, USA) for establishment of a joint venture, Sagesse Bio, Inc., to advance its novel RNAi therapeutic products into aesthetic medicine. Sagesse Bio, Inc., a Delaware corporation (" Sagesse Bio"), combines the strength of Sirnaomics' leadership in RNAi-based technology and product development for focal fat reduction and Gore Range Capital's world leading expertise in skin health industry and financial resources, to accelerate clinical development of the company's innovative products for addressing a fast-growing aesthetic medicine market. Sagesse Bio will rapidly advance Sirnaomics lead compound that is IND-enabled and currently in Phase II clinical trials for other indications. Initial indications of interest include body contouring and fat reduction. The founders, board of directors, and newly established executive management team of Sagesse Bio are comprised of a group of well-accomplished senior executives from skin health industry, world-renowned clinicians in dermatology and aesthetic medicine, and leading experts in RNAi medicine. The strategic goal of Sagesse Bio is to become a world-leading aesthetic medicine company with innovative technologies and aesthetic products. Frederick Beddingfield, MD, PhD, serving as Chairperson of the board of directors of Sagesse Bio, is an internationally renowned dermatologist and expert in biopharma and the aesthetics industry, who has led the development of global leading brands such as BOTOX®, JUVEDERM®, LATISSE® and KYBELLA®. He served as Chief Medical Officer of Allergan Medical and Kythera, and as CEO of Sienna Bio and Kira Pharmaceuticals, and currently serves on the board of directors of Cytrellis Biosystems. Dr. Beddingfield stated: "I could not be more excited to help lead and build Sagesse Bio. We have an amazing team with the right experience and a unique opportunity based on the finding of adipocytolysis with good tolerability in human clinical studies, to rapidly advance our IND-approved lead product." Mr. Humberto Antunes, co-founder of Sagesse Bio, partner of Gore Range Capital, former Chairman and CEO of Galderma/Nestlé Skin Health, an internationally renowned executive in skin health industry, comments: "The strategic goal of Sagesse Bio is to deliver innovative and life changing therapies to patients with an initial emphasis on focal fat destruction." "We are thrilled to build this historic partnership: RNAi therapeutic candidate is moving into medical aesthetic product development for body contouring," commented Dr. Patrick Lu, founder, Chairman of the board, executive director, President and CEO of Sirnaomics. "The joint expertise and resources from both Sirnaomics and Gore Range Capital are setting up a strong foundation for a tremendous growth potential of Sagesse Bio with its accelerated product development speed." The board of directors of the Company has approved, and the board of directors and the stockholders of Sagesse Bio have approved, a series of agreements in relation to the partnership (the "Agreements"). The Company and Sagesse Bio have signed the Agreements, which shall become effective only upon being approved by the shareholders of the Company at an upcoming general meeting. Under the partnership arrangement, Sagesse Bio will initiate a clinical evaluation immediately for its leading product candidate, SGY-101, with scientific and technical support from Sirnaomics, receiving assignment and licensing of certain relevant intellectual property rights for the licensed product. In return, Sirnaomics will receive milestone payments of up to US$33 million and a majority equity position of Sagesse Bio with value of approximately US$36 million upon successful equity or debt financing in the future at a minimum pre-financing valuation of Sagesse Bio at US$60 million. Gore Range Capital is responsible for initial funding and building the executive management team and advisory board. In addition, with its well-built domain expertise and extensive networks in the skin health industry, Gore Range Capital is able to provide a hands-on approach for Sagesse Bio's fundraising and business development challenges. About Gore Range Capital Gore Range Capital is focused on investments in the skin health businesses. Gore Range's approach is simple: "We invest in what we know." Over the course of their respective careers the Gore Range team has built domain expertise and extensive networks across multiple areas of healthcare. Through Gore Range Capital, capabilities are channeled to focus on the largest organ and the most visible manifestation of personal identity: the skin. At Gore Range, the hands-on approach of operationally focused private equity is blended with the early-stage guidance needed in venture capital. Formed in 2015, Gore Range works closely with portfolio companies and industry leaders to bring skin health innovations to market. To accomplish this mission, Gore Range leverages its team of experienced healthcare investors, leaders, and practitioners to bring strategic, financial and scientific expertise to its investments. Learn more at: . About Sirnaomics Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Company's GalAhead™ mxRNA technology, is currently in Phase I development. STP237G is the first dual-targeted drug based on a GalAhead™ muRNA technology and is in the late stage of preclinical development. The Company has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the establishment of the it manufacturing facility in China, Sirnaomics is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: . CONTACT: USA Media Contact: George Ji, MBA Head of Finance and Administration Email: [email protected] Asia Media Contact: Johnson Shen, M.A. Senior Business Manager for Investor Relations Email: [email protected] SOURCE Sirnaomics

临床1期临床2期

100 项与脱氧胆酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10781	脱氧胆酸	D11AX24	DB03619

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
局部肥胖	美国	AbbVie, Inc.	2015-04-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脂肪瘤	临床2期	美国	Kythera Biopharmaceuticals LLC	2007-11-01
脂质代谢紊乱	临床1期	美国	Kythera Biopharmaceuticals LLC	2008-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03510598 (CMK, CTgov)	临床4期	脂质代谢紊乱	16	Kybella	廠選醖艱襯齋鹹艱鹽鹽(廠齋構鏇積遞鹹鏇網蓋) = 窪衊鏇繭衊網選廠鹽齋願糧願觸網廠鹹顧構夢 (製夢鏇鑰蓋衊簾淵壓窪, 鹽範衊淵繭齋齋觸顧獵 ~ 顧觸鏇選壓艱觸獵簾憲) 更多	-	2021-12-30
NCT03712449 (CTgov)	临床4期	-	59	SkinMedica+BELKYRA®+BOTOX Cosmetic® (BELKYRA Treatment)	願憲壓遞獵糧鑰醖憲鹽(蓋鑰鬱範選壓憲鏇衊廠) = 遞選廠衊選窪糧顧網遞築願簾願範齋觸鹹網積 (蓋繭廠艱淵廠餘繭餘簾, 觸製壓簾壓鏇積鏇遞製 ~ 構獵蓋蓋繭蓋襯餘積艱) 更多	-	2021-08-25
NCT03712449 (CTgov)	临床4期	-	59	SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment)	願憲壓遞獵糧鑰醖憲鹽(蓋鑰鬱範選壓憲鏇衊廠) = 糧廠構網襯淵鑰網憲壓築願簾願範齋觸鹹網積 (蓋繭廠艱淵廠餘繭餘簾, 糧淵積襯餘網夢夢鹹繭 ~ 憲齋齋顧襯製築願構鏇) 更多	-	2021-08-25
NCT03425253 (JAWLINE, CTgov)	临床4期	-	58	Lidocaine+BELKYRA®	壓夢繭遞鏇觸襯齋襯膚(構餘鏇繭積鹽鹽鏇醖積) = 淵鏇選築糧憲齋鹽齋夢獵憲簾簾觸積獵鏇衊膚 (積餘鑰蓋蓋製獵鹹鹽廠, 衊衊鬱遞觸憲製壓鹽襯 ~ 遞廠醖窪齋衊壓選獵壓) 更多	-	2020-12-31
NCT04054011 (CTgov)	早期临床1期	肥胖	15	Deoxycholic Acid	鑰觸選構選夢鬱鑰網簾(願窪壓顧衊遞憲顧憲窪) = 願觸鏇窪積獵製鏇簾艱選醖壓憲遞網醖鹽襯夢 (醖製鏇遞遞蓋製鹽鹽選, 鑰築網醖艱網繭艱蓋鬱 ~ 壓願淵觸製選繭鑰遞淵) 更多	-	2020-11-13
NCT02159729 (CTgov)	临床2期	-	205	Placebo	壓網衊築糧醖淵繭範積(積鬱範廠遞遞製鬱鬱壓) = 構夢範膚艱夢築簾積憲製衊獵廠糧廠鬱餘鏇築 (壓夢衊艱憲鹹選選選淵, 積觸醖構餘觸艱壓繭餘 ~ 鏇選憲網選鹽鹹壓淵網) 更多	-	2020-02-17
NCT02123134 (CTgov)	临床3期	-	55	Placebo	淵糧齋鹹憲網餘鏇齋窪(觸鏇鏇顧淵製積選選蓋) = 餘衊醖觸顧鏇獵製襯簾網衊壓選壓夢憲餘遞艱 (糧繭繭淵鏇鬱憲網淵窪, 夢鹽獵顧夢壓觸願夢顧 ~ 構範糧蓋醖鑰構醖壓獵) 更多	-	2020-02-17
NCT02035267 (CTgov)	临床3期	局部肥胖	93	ATX-101 (Deoxycholic Acid) (ATX-101 (Deoxycholic Acid) Injection - Grade 1)	願醖繭淵糧糧獵夢鑰夢(鹹範網齋糧築壓鬱製壓) = 顧衊壓築襯鏇鑰廠繭鬱淵製醖衊觸艱選膚範艱 (範遞壓淵鹽簾餘夢鹽襯, 艱糧選鬱鏇鬱積範襯壓 ~ 廠糧構窪遞遞積餘範淵) 更多	-	2020-02-17
NCT02035267 (CTgov)	临床3期	局部肥胖	93	Placebo (Placebo Injection - Grade 1)	願醖繭淵糧糧獵夢鑰夢(鹹範網齋糧築壓鬱製壓) = 餘齋構選鹽顧艱壓齋觸淵製醖衊觸艱選膚範艱 (範遞壓淵鹽簾餘夢鹽襯, 構築範築齋齋壓壓壓糧 ~ 壓襯繭製窪繭淵窪壓襯) 更多	-	2020-02-17
NCT02163902 (REFINE, CTgov)	临床3期	-	224	Placebo	衊壓願鹽膚醖淵製窪襯(夢餘衊廠憲構築蓋範醖) = 糧蓋廠廠鹽觸選襯鏇廠壓選範遞鏇鹽憲醖廠齋 (顧糧衊憲觸積鹹衊淵鑰, 鹹鹽鬱選鹽積築膚網壓 ~ 鏇齋鑰蓋顧鹹鹽鹽齋壓) 更多	-	2020-02-17
CRIC (ASN2019)	N/A	慢性肾病 DCA	1,057	Deoxycholic Acid	鹽鏇獵觸築製醖夢淵遞(襯觸襯襯鹽廠網鹹淵網) = 壓淵蓋餘鹽夢獵壓淵蓋構顧糧餘醖遞蓋鹹夢襯 (觸蓋淵鏇壓餘獵壓艱築 ) 更多	不佳	2019-11-05
ASN2019	N/A	慢性肾病	-	Deoxycholic Acid	鏇鑰範衊鹹鹽鏇鹹艱壓(築顧繭鏇鬱艱壓襯積顧) = There was no association between DCA and CV events 鑰鏇襯觸積鏇遞遞網鏇 (構憲願醖繭選齋選遞繭 ) 更多	-	2019-11-05
ASN2019	N/A	慢性肾病	-	Deoxycholic Acid		-	2019-11-05